Global Left Ventricular Dysfunction - API Manufacturers, Marketed and Phase III Drugs Landscape 2018 - ResearchAndMarkets.com

December 19, 2018

DUBLIN--(BUSINESS WIRE)--Dec 19, 2018--The “Left Ventricular Dysfunction - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The ‘Left Ventricular Dysfunction - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018’ report provides comprehensive insights about marketed and Phase III products for Left Ventricular Dysfunction. The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country.

Global API Manufacturers of Marketed Products for Left Ventricular Dysfunction

Coverage of API manufacturers for Left Ventricular Dysfunction marketed products spanning across United States, Europe, China and India. The manufacturers’ details include manufacturers’ name along with their location.

Emerging Phase III products for Left Ventricular Dysfunction

This report provides a comprehensive understanding of the emerging Phase III therapies for Left Ventricular Dysfunction which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2020.

Key Topics Covered:

1. Report Introduction

2. Left Ventricular Dysfunction: Overview

Risk FactorsCausesSymptomsPathophysiologyPrognosisDiagnosisTreatment

3. Comparative Analysis of Marketed and Emerging Products

4. Marketed Therapies

Product DescriptionRoute of SynthesisMechanism of ActionPharmacologyPharmacodynamicsPharmacokineticsAdverse ReactionsClinical TrialsRegulatory MilestonesProduct Development ActivitiesUnited StatesEuropeHistorical Global SalesForecasted Global Sales

5. Emerging Therapies (Phase III)

Product DescriptionResearch and DevelopmentProduct Development Activities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/6mng35/global_left?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181219005332/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/19/2018 06:43 AM/DISC: 12/19/2018 06:43 AM


Update hourly